Last updated on January 2019

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer


Brief description of study

The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.

Clinical Study Identifier: NCT03371979

Contact Investigators or Research Sites near you

Start Over

Taofeek Owonikoko, MD

Emory University
Atlanta, GA United States
  Connect »

Shirish Gadgeel, MD

University of Michigan
Ann Arbor, MI United States
  Connect »

Hirva Mamdani, MD

Karmanos Cancer Institute
Detroit, MI United States
  Connect »

Siddartha Devarakonda, MD

Washington University
Saint Louis, MO United States
  Connect »

Rachel Sanborn, MD

Providence Cancer Center
Portland, OR United States
  Connect »

David Spigel, MD

Sarah Cannon Research Institute
Nashville, TN United States
  Connect »

Mirelis Acosta-Rivera, MD

Fundacion De Investigacion, Hematology/Oncology
San Juan, Puerto Rico
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.